Semmelweis University – News
The Semmelweis Biobank Network, the BBMRI Hungarian National Node, which is Europe’s largest biobank network, the National Cardiovascular Laboratory and the Hungarian Center of Excellence for Molecular Medicine (HCEMM) have been included in the top 50 Hungarian research infrastructures compiled by the National Research, Development and Innovation Office (NFKI), and classified as excellent research infrastructures.
An innovative rapid test at least a year ahead of the international market is being developed and promoted by a European consortium involving Semmelweis University under the project coordination of its Health Services Management Training Centre (EMK). The tested device is expected to fundamentally redefine the diagnosis of antibiotic-resistant bacteria within a few years. Unfortunately, these pathogens are currently responsible for more than 30,000 deaths in Europe every year, and in the absence of new types of drugs, rapid diagnosis and targeted therapy are more important than ever.
Experience and guidelines to date have been confirmed by recently published international research showing that the COVID-19 vaccine does not cause any noticeable negative changes in fertility, according to leading obstetrician-gynecology professors at Semmelweis University. However, the study confirmed the already observed effect that coronavirus infection can temporarily reduce men’s fertility. Vaccination of women planning pregnancy, including those planning in vitro fertilization, is strongly recommended, as is vaccination of pregnant and breastfeeding mothers, leaders of the university’s Department of Obstetrics and Gynecology pointed out once again in light of the new study.
The software developed by Semmelweis University in cooperation with Neumann Medical Ltd. and Arineta Ltd. significantly simplifies the process of cardiac CT scans’ interpretation and image analysis, thus speeding up the diagnosis. The core of the platform created within the project is a workstation, which connects image analysis, evaluation and clinical care needs, guided by structured data input.
Semmelweis University and AstraZeneca’s Hungarian subsidiary have signed a strategic cooperation agreement to further investigate the links between certain common diseases, such as diabetes, chronic kidney disease (CKD) and heart failure, to strengthen and expand joint research and development activities, and to implement joint programmes to help treat, educate and diagnose patients. A framework agreement for clinical trials was also signed at the event, which will allow for faster and more efficient trial start-ups.